With the rapid acceleration of telehealth solutions brought about by the pandemic, one company is uniquely servicing a key demographic- expectant mothers.
Medtech HeraMED (ASX: HMD) is moving obstetric care into 2021 with their comprehensive digital health platform, HeraCARE and associated fetal and maternal heart rate monitor, HeraBEAT. The clinically validated tech allows for remote monitoring of both fetal and maternal health, and has the capability to detect issues before they arise.
HeraCARE has been designed to deliver high quality, low touch pre and postnatal care to mothers. The fully integrated platform allows for data collection and sharing across the whole health care team including obstetrician, GP and midwives.
A pilot program for the tech at the Joondalup Health Campus (JHC) in Perth, Western Australia was initiated in mid-August and aimed to establish metrics around usability and adherence to the program.
JHC is a part of Ramsay Health Care and is a leading Western Australian hospital with a prominent maternity care department, providing care to an average of 3000 expectant mothers per year.
The paid pilot program saw 100 expectant mothers utilise the HeraCARE system. The Company has released interim results which provide insight into the pilot, and further support the upcoming commercial roll out of the system.
Early results are promising with 96% of expectant mothers having been on boarded and are using the system regularly. High patient adherence is key, and speaks to the usability of the system. 94% of women in the program reported that they enjoy taking measurements remotely and 93% would recommend the system to a friend.
Women in the pilot gave the system an overall patient score of 94% (4.7/5).
The promising results stem from the work of HeraMED’s team and dedicated local project manager who have been working alongside JHC’s obstetrics department. The team have worked to align the HeraCARE platform with JHC’s unique requirements and provide training to staff.
Following the paid pilot program, JHC will use HeraMED’s Technology- as-a- Service on an ongoing basis. The pilot arose after a successful clinical study of the tech which was undertaken at JHC which showed that the device and platform were found to exceed the current industry standard machines.
HeraMED CEO David Groberman commented on the pilot’s progress, saying: “As part of Australia’s largest private hospital operator, Ramsay Health Care Group, JHC are well regarded as early adopters of new technologies in obstetrics. I am proud to see the paid pilot is progressing very well, showing positive results and excellent adherence statistics. This is another strong validation of our platform’s efficiency, ease of use, and seamless integration. We believe the pilot is approaching the final stages, and we are looking forward to strengthening our collaboration with JHC in order to be able to offer the innovative service to their entire audience of pregnant mothers.”
The pilot is anticipated to be complete early next year.
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
- Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial - September 1, 2022
- How this company is developing medtech to support Indigenous community health - August 22, 2022
- A round of ap-paws for PharmAust, changing the ruff prognosis for dogs with lymphoma - August 17, 2022
Leave a Comment
You must be logged in to post a comment.